Effect of a Reminder System on Pre-exposure Prophylaxis Adherence in Men Who Have Sex With Men: Prospective Cohort Study Based on WeChat Intervention.
HIV prevention
MSM
WeChat
adherence
men who have sex with men (MSM)
message
oral PrEP
pre-exposure prophylaxis (PrEP)
reminder
reminder system
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
11 08 2022
11 08 2022
Historique:
received:
12
03
2022
accepted:
12
07
2022
revised:
16
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
The efficacy of pre-exposure prophylaxis (PrEP) is highly dependent on adherence, and one of the main reasons for poor adherence is forgetfulness. Therefore, it is important to explore how to remind users to take their medicine on time. This study aims to explore the effect of a reminder system on PrEP adherence in men who have sex with men (MSM) to improve adherence. The main function of the reminder system based on the WeChat social media app is to send daily messages to PrEP users reminding them to take their medicine. An open-label, multicenter, prospective cohort study of PrEP in HIV-negative MSM was conducted from November 2019 to June 2021. Study participants who met the criteria were randomly divided into 2 groups: no-reminder group and reminder group. Both groups received daily oral PrEP with follow-up every 3 months. Adherence was measured on the basis of self-report and was defined as the percentage of medications taken on time. Participants in the reminder group scanned a WeChat QR code and received a reminder message every day. Participants in the no-reminder group took daily oral medicines without reminders. The longitudinal trajectories of adherence for both groups were displayed to compare the variability in adherence at each time point. The association between the changes in adherence (no change, improvement, decline) at each time point and the use of the reminder system was analyzed by multinomial logistic regression models to further explore the effectiveness of the system. A total of 716 MSM were included in the analysis, that is, 372 MSM in the no-reminder group and 344 MSM in the reminder group. Adherence in the no-reminder group fluctuated between 0.75 and 0.80 and that in the reminder group gradually increased over time from 0.76 to 0.88. Adherence at each time point was not statistically different between the 2 groups. Further analysis showed that an improvement in adherence in the early stage was associated with the use of the reminder system (odds ratio [OR] 1.65, 95% CI 1.01-2.70; P=.04). An improvement in average adherence compared to initial adherence was positively associated with the use of the reminder system (OR 1.82, 95% CI 1.10-3.01; P=.02). The effect of the reminder system on PrEP adherence in MSM was more significant in the early stage, which is related to the increased motivation of users and the development of medicine-taking habits. The reminder system is potentially effective for early-stage medicine management, encouraging users to develop healthy medicine-taking habits and to increase their adherence. Chinese Clinical Trial ChiCTR190026414; http://www.chictr.org.cn/showproj.aspx?proj=35077.
Sections du résumé
BACKGROUND
The efficacy of pre-exposure prophylaxis (PrEP) is highly dependent on adherence, and one of the main reasons for poor adherence is forgetfulness. Therefore, it is important to explore how to remind users to take their medicine on time.
OBJECTIVE
This study aims to explore the effect of a reminder system on PrEP adherence in men who have sex with men (MSM) to improve adherence. The main function of the reminder system based on the WeChat social media app is to send daily messages to PrEP users reminding them to take their medicine.
METHODS
An open-label, multicenter, prospective cohort study of PrEP in HIV-negative MSM was conducted from November 2019 to June 2021. Study participants who met the criteria were randomly divided into 2 groups: no-reminder group and reminder group. Both groups received daily oral PrEP with follow-up every 3 months. Adherence was measured on the basis of self-report and was defined as the percentage of medications taken on time. Participants in the reminder group scanned a WeChat QR code and received a reminder message every day. Participants in the no-reminder group took daily oral medicines without reminders. The longitudinal trajectories of adherence for both groups were displayed to compare the variability in adherence at each time point. The association between the changes in adherence (no change, improvement, decline) at each time point and the use of the reminder system was analyzed by multinomial logistic regression models to further explore the effectiveness of the system.
RESULTS
A total of 716 MSM were included in the analysis, that is, 372 MSM in the no-reminder group and 344 MSM in the reminder group. Adherence in the no-reminder group fluctuated between 0.75 and 0.80 and that in the reminder group gradually increased over time from 0.76 to 0.88. Adherence at each time point was not statistically different between the 2 groups. Further analysis showed that an improvement in adherence in the early stage was associated with the use of the reminder system (odds ratio [OR] 1.65, 95% CI 1.01-2.70; P=.04). An improvement in average adherence compared to initial adherence was positively associated with the use of the reminder system (OR 1.82, 95% CI 1.10-3.01; P=.02).
CONCLUSIONS
The effect of the reminder system on PrEP adherence in MSM was more significant in the early stage, which is related to the increased motivation of users and the development of medicine-taking habits. The reminder system is potentially effective for early-stage medicine management, encouraging users to develop healthy medicine-taking habits and to increase their adherence.
TRIAL REGISTRATION
Chinese Clinical Trial ChiCTR190026414; http://www.chictr.org.cn/showproj.aspx?proj=35077.
Identifiants
pubmed: 35969436
pii: v24i8e37936
doi: 10.2196/37936
pmc: PMC9412721
doi:
Substances chimiques
Anti-HIV Agents
0
Tenofovir
99YXE507IL
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e37936Informations de copyright
©Bing Lin, Jiaxiu Liu, Wei He, Haiying Pan, Yingjie Ma, Xiaoni Zhong. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 11.08.2022.
Références
J AIDS Clin Res. 2017;8(1):
pubmed: 30140549
PLoS One. 2012;7(3):e33119
pubmed: 22470438
AIDS Behav. 2021 Apr;25(4):1001-1012
pubmed: 33044687
Curr Opin HIV AIDS. 2012 Nov;7(6):593-9
pubmed: 23032736
JMIR Mhealth Uhealth. 2013 Jul 30;1(2):e17
pubmed: 25098502
AIDS. 2016 May 15;30(8):1287-94
pubmed: 26807967
J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):13-20
pubmed: 25296098
AIDS Behav. 2016 Nov;20(11):2629-2638
pubmed: 26781866
AIDS Behav. 2013 Jan;17(1):284-97
pubmed: 22407465
PLoS One. 2019 Aug 20;14(8):e0221281
pubmed: 31430318
Lancet. 2014 Feb 1;383(9915):399-400
pubmed: 24494225
BMC Med Inform Decis Mak. 2017 Jul 5;17(Suppl 2):66
pubmed: 28699549
Risk Manag Healthc Policy. 2021 Apr 28;14:1749-1761
pubmed: 33953624
AIDS Behav. 2018 Apr;22(4):1063-1074
pubmed: 28176168
AIDS Res Ther. 2020 Jun 8;17(1):30
pubmed: 32513192
HIV Clin Trials. 2011 Sep-Oct;12(5):244-54
pubmed: 22180522
J Med Internet Res. 2021 Oct 26;23(10):e28508
pubmed: 34698651
AIDS Care. 2020 Feb;32(2):255-260
pubmed: 31242753
AIDS. 2021 Mar 1;35(3):463-475
pubmed: 33252486
Clin Infect Dis. 2017 Apr 01;64(7):956-963
pubmed: 28362948
AIDS Behav. 2012 Jul;16(5):1243-59
pubmed: 22460228
Lancet HIV. 2018 Mar;5(3):e136-e145
pubmed: 29467098
Int J STD AIDS. 2020 Jul;31(8):735-746
pubmed: 32631214
AIDS Behav. 2015 May;19(5):794-801
pubmed: 25432877
J Biomed Inform. 2018 Apr;80:78-86
pubmed: 29501908
Medicine (Baltimore). 2017 Feb;96(7):e6078
pubmed: 28207516
BMJ Open. 2013 Dec 17;3(12):e003950
pubmed: 24345901
Health Educ Res. 1997 Sep;12(3):363-74
pubmed: 10174219
AIDS Care. 2018 Feb;30(2):191-198
pubmed: 28830220
JMIR Mhealth Uhealth. 2018 Sep 04;6(9):e10274
pubmed: 30181109
Evid Based Complement Alternat Med. 2014;2014:376058
pubmed: 24527045
AIDS. 2016 Apr 24;30(7):1121-9
pubmed: 26785125
AIDS Behav. 2019 May;23(5):1267-1276
pubmed: 30406335
AIDS Behav. 2017 Nov;21(11):3100-3110
pubmed: 28025735
BMJ Open. 2019 Jan 3;9(1):e023498
pubmed: 30610021
Int J Infect Dis. 2018 Oct;75:52-59
pubmed: 30125688
PLoS One. 2014 Feb 05;9(2):e88166
pubmed: 24505411
Health Psychol Rev. 2015;9(3):277-95
pubmed: 25207647
Lancet HIV. 2021 Mar;8(3):e130-e137
pubmed: 33662265
Patient Prefer Adherence. 2020 Jan 16;14:107-118
pubmed: 32021122
Expert Rev Clin Pharmacol. 2014 Sep;7(5):633-44
pubmed: 25088004
AIDS Care. 2020 Feb;32(2):249-254
pubmed: 31159584
Infect Dis Ther. 2016 Dec;5(4):407-416
pubmed: 27677264
AIDS Care. 2020 Aug;32(8):1014-1022
pubmed: 32336130
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
AIDS Care. 2017 Sep;29(9):1144-1148
pubmed: 28478706
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Clin Nurs Res. 2022 Mar;31(3):426-434
pubmed: 34287084
AIDS Behav. 2013 Nov;17(9):2977-85
pubmed: 23695519
Mhealth. 2019 Feb 14;5:4
pubmed: 30976596